Article Text

Download PDFPDF
Inhaled insulin added onto or replacing 2 oral agents reduced haemoglobin A1c concentrations in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with type 2 diabetes mellitus, does inhaled insulin added onto or replacing a failing regimen with 2 oral agents reduce haemoglobin A1c (HbA1c) concentrations?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Internal medicine ★★★★★★★ Endocrine ★★★★★☆☆


Embedded ImageDesign:

randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:


Embedded ImageFollow up period:

12 weeks.

Embedded ImageSetting:

48 outpatient centres in the US and Canada.

Embedded ImagePatients:

309 patients 35–80 years of age (mean age 57 y, 65% men) with ⩾1 year history of type 2 diabetes treated with a stable oral agent regimen (1 insulin secretagogue and 1 insulin sensitiser) and HbA1c of 8–11%. Exclusion criteria included predisposition to severe hypoglycaemia; hospital admission or emergency department visit for poor diabetic control in previous 6 months; …

View Full Text


  • * See glossary

  • For correspondence: Dr J Rosenstock, Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA. juliorosenstock{at}

  • Sources of funding: Pfizer Inc and Sanofaventis Group.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd